Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/12/2017 10/13/2017 10/16/2017 10/17/2017 10/18/2017 Date
81.3(c) 81.17(c) 79.95(c) 80.24(c) 79.9 Last
6 763 601 5 682 947 7 377 562 7 041 810 2 910 766 Volume
-1.54% -0.16% -1.50% +0.36% -0.42% Change
More quotes
Financials ($)
Sales 2017 25 836 M
EBIT 2017 16 052 M
Net income 2017 10 607 M
Debt 2017 12 394 M
Yield 2017 2,64%
Sales 2018 22 857 M
EBIT 2018 13 268 M
Net income 2018 8 751 M
Debt 2018 9 663 M
Yield 2018 2,83%
P/E ratio 2017 10,02
P/E ratio 2018 11,79
EV / Sales2017 4,54x
EV / Sales2018 5,01x
Capitalization 105 B
More Financials
Company
Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need.It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology &... 
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
05:49p GILEAD SCIENCES : UMass Medical Center and Dana-Farber Cancer Institute to recei..
03:02p GILEAD SCIENCES : Jay Flatley and John Martin to Be Named Recipients of Life Sci..
10:07a GILEAD SCIENCES : Awards $7.5 Million in Second Round of Grants to Advance HIV C..
04:35a GILEAD SCIENCES : UMass Medical School shares $7.5M HIV grant
10/17 GILEAD SCIENCES : Announces Promotion of Alessandro Riva to Executive Vice Presi..
10/16 GILEAD SCIENCES : Awards $7.5 Million in Second Round of Grants to Advance HIV C..
10/16 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday Oc..
10/12 GILEAD SCIENCES : An Application for the Trademark "NASH360" Has Been Filed by G..
10/12 GILEAD SCIENCES : High-Stakes Gilead Case Lands Fish & Richardson Principals Jua..
10/12 GILEAD SCIENCES : Completes Acquisition of Kite Pharma, Inc.
More news
Sector news : Bio Therapeutic Drugs
08:48aDJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
10/17DJJOHNSON & JOHNSON : Raises Guidance on Earnings Beat
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on GILEAD SCIENCES 
GILEAD SCIENCES - 2014
A valuable trading opportunity
BUY
GILEAD SCIENCES - 2014
Continuation of the bullish trend
BUY
More Strategies
Latest Tweets
05:54p  
05:06pGilead Sciences downgraded by Zacks Investment Research to sell.  
05:00p  
04:52p  
02:46pArthur Hill: Three Pullbacks for Three Healthcare Stocks $GILD $AMGN $MRK  
More tweets
Qtime:396
News from SeekingAlpha
11:54a The Math Behind the Gilead's Recent Merger
10:51a NETFLIX : Why It's Dangerous To Own Now
10/17 YOUR DAILY PHARMA SCOOP : Everybody's Gilead Problem, Halozyme's Further Progres..
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 GILEAD : My Only 'Buy 'Til You Die' Investment,  A Deep Due Diligence Dive
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 84,2 $
Spread / Average Target 4,9%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES11.65%104 788
REGENERON PHARMACEUTICALS20.67%47 421
VERTEX PHARMACEUTICALS107.56%39 091
ACTELION23.24%29 925
GENMAB22.08%13 010
EXELIXIS, INC.66.06%8 318